5 Top Losers In Healthcare Sector (RGLS, CTST, MRNS…)

pharmadown july24

The following are some of the healthcare stocks that posted the biggest percentage decline on Wednesday.

1. Regulus Therapeutics Inc. (RGLS)

Regulus is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs.

Lost 34.81% to close Wednesday's (July 24) trading at $0.74.

News: The Company's Phase I multiple ascending dose study for its autosomal dominant polycystic kidney disease (ADPKD) candidate RGLS4326 has been placed on partial clinical hold by the FDA.

Last July, Regulus voluntarily paused its phase I clinical program of RGLS4326 due to unexpected findings in the mouse chronic toxicity study being run in parallel with the Phase 1 program.

The Company has been asked by the FDA to submit additional nonclinical data requirements before it can reinitiate the multiple ascending dose study and further proceed into chronic dosing in ADPKD. patients.

2. CannTrust Holdings Inc. (CTST)

CannTrust is a federally licensed provider of medical cannabis.

Lost 22.14% to close Wednesday's trading at $2.04.

News: CannTrust, which is already in the crosshairs of Health Canada for the growing of cannabis in five unlicensed rooms and for providing inaccurate information to the regulator, took a hit, following a new report by The Globe and Mail.

The report claims that Chairman Eric Paul and CEO Peter Aceto were well aware of the non-compliance of their greenhouse facility in Pelham, Ontario months before Health Canada pulled up the Company.

3. Marinus Pharmaceuticals Inc. (MRNS)

Marinus is a biopharmaceutical company developing innovative therapeutics to treat epilepsy and neuropsychiatric disorder. Its lead drug candidate is Ganaxolone, which is being developed in three different dose forms, IV, capsule and liquid.

Lost 18.29% to close Wednesday's trading at $0.97. This is the second straight day of loss for the stock.

Recent event:

On July 23, 2019, the Company announced results from Part 2 of its phase II clinical trial evaluating IV Ganaxolone followed by daily oral Ganaxolone in women with postpartum depression, dubbed Magnolia.

Although the results showed that Ganaxolone administered as a six-hour infusion followed by oral administration was generally safe, well-tolerated and provided clinically meaningful reductions in Hamilton Rating Scale for Depression (HAM-D17) scores at early time points of 6 hours and 24 hours after start of treatment, the HAM-D17 scores at 28 days of treatment were not different from placebo.

4. Chiasma Inc. (CHMA)

Chiasma is a clinical-stage biopharmaceutical company developing drugs for rare and serious chronic diseases.

The Company's lead drug candidate is MYCAPSSA (octreotide capsules), being developed as a maintenance treatment for adult patients with acromegaly.

Lost 17.30% to close Wednesday's trading at $6.50. The stock has given back nearly all it gained on Tuesday.

Recent event:

On Tuesday, July 23, 2019, the Company announced positive top-line data from its pivotal phase III clinical trial of MYCAPSSA for the maintenance treatment of adults with acromegaly, dubbed CHIASMA OPTIMAL.

The trial met the primary endpoint - with 58% of the patients on MYCAPSSA maintaining their IGF-1 response compared to 19% of the patients on placebo.

Near-term Catalyst:

The Company plans to submit an NDA for MYCAPSSA for the maintenance treatment for adult patients with acromegaly by the end of this year.

5. Enlivex Therapeutics Ltd. (ENLV)

Enlivex is a clinical-stage immunotherapy company.

Lost 14.16% to close Wednesday's trading at $20.00.

News: No news

Clinical Trials & Near-term Catalysts:

The Company's lead product candidate is ALLOCETRA.

-- A phase IIa clinical study of Allocetra for preventing post- bone marrow transplantation (BMT) complications has been completed. A continuation Phase II/III clinical trial with Allocetra further investigating its use for the prevention of complications post bone-marrow transplantation is expected to be initiated by early 2020.
-- A Phase II trial for the prevention of post-BMT complications in steroid-refractory Graft versus host disease (GvHD) patients is expected to be initiated during 2020.
-- A phase II trial of ALLOCETRA studying the prevention of cytokine storms and organ dysfunction associated with sepsis is expected to be initiated in Q4, 2019. A phase Ib study in this indication is ongoing.

Recent events:

-- On July 22, 2019, the Company's shares were dual-listed on the Tel Aviv Stock Exchange, under the symbol ENLV.
-- On April 8, the Company announced the final closing of a private placement financing of ordinary shares priced at $12.25 per share, raising a total of approximately $8.4 million.
-- Enlivex Therapeutics was listed to the NASDAQ on March 26, 2019.
-- Enlivex Therapeutics Ltd is the result of the merger of publicly-traded Bioblast Pharma Ltd. with Enlivex Therapeutics Ltd., a VC-funded privately-held immunotherapy company. The merger agreement was executed on November 19, 2018.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT